avril 24, 2025 DUO25 | April 24-26, 2025 Register now for DUO25, a hybrid congress that unites obesity & diabetes HCP's in Canada.
février 21, 2025 Clinical Cardiology & Care Update 2025 (IN PERSON) This new one-day conference will be held at U of T: Schwartz Reisman Innovation Campus
11:26 Diabetes Update 2022 Podcast Series Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology
59:51 A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in CKD
février 21, 2025 Clinical Cardiology & Care Update 2025 (IN PERSON) This new one-day conference will be held at U of T: Schwartz Reisman Innovation Campus
06:18 AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
06:14 AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
59:51 A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in CKD
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs
06:18 AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
06:14 AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
03:14 AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
04:48 AIM-LO: Engaging With Your Patients about Selection of Injectable Therapies for Engaging With Your Patients about Selection of Injectable Therapies for LDL-C Reduction
11:26 Diabetes Update 2022 Podcast Series Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology
13:33 Diabetes Update 2022 Podcast Series Incorporating Novel Cardiovascular (Cv) Risk Reduction Strategies for Diabetes Patients: W